id	sid	tid	token	lemma	pos
dpc-4195	1	1	dermatology	dermatology	NOUN
dpc-4195	1	2	:	:	PUNCT
dpc-4195	1	3	practical	practical	ADJ
dpc-4195	1	4	and	and	CCONJ
dpc-4195	1	5	conceptual	conceptual	ADJ
dpc-4195	1	6	research	research	NOUN
dpc-4195	1	7	letter	letter	NOUN
dpc-4195	2	1	|	|	ADV
dpc-4195	2	2	dermatol	dermatol	ADJ
dpc-4195	2	3	pract	pract	NOUN
dpc-4195	2	4	concept	concept	NOUN
dpc-4195	2	5	.	.	PUNCT
dpc-4195	3	1	2024;14(3):e2024186	2024;14(3):e2024186	NUM
dpc-4195	3	2	1	1	NUM
dpc-4195	3	3	real	real	ADJ
dpc-4195	3	4	-	-	PUNCT
dpc-4195	3	5	world	world	NOUN
dpc-4195	3	6	experience	experience	NOUN
dpc-4195	3	7	of	of	ADP
dpc-4195	3	8	upadacitinib	upadacitinib	NOUN
dpc-4195	3	9	dosing	dose	VERB
dpc-4195	3	10	reduction	reduction	NOUN
dpc-4195	3	11	in	in	ADP
dpc-4195	3	12	patients	patient	NOUN
dpc-4195	3	13	with	with	ADP
dpc-4195	3	14	moderate	moderate	ADJ
dpc-4195	3	15	atopic	atopic	NOUN
dpc-4195	3	16	dermatitis	dermatitis	NOUN
dpc-4195	3	17	:	:	PUNCT
dpc-4195	3	18	a	a	DET
dpc-4195	3	19	case	case	NOUN
dpc-4195	3	20	series	series	NOUN
dpc-4195	3	21	study	study	NOUN
dpc-4195	3	22	in	in	ADP
dpc-4195	3	23	taiwan	taiwan	PROPN
dpc-4195	3	24	yang	yang	PROPN
dpc-4195	3	25	-	-	PUNCT
dpc-4195	3	26	yi	yi	PROPN
dpc-4195	3	27	chen1,2	chen1,2	PROPN
dpc-4195	3	28	,	,	PUNCT
dpc-4195	3	29	chieh	chieh	PROPN
dpc-4195	3	30	-	-	PUNCT
dpc-4195	3	31	hsun	hsun	PROPN
dpc-4195	3	32	chen1	chen1	PROPN
dpc-4195	3	33	,	,	PUNCT
dpc-4195	3	34	cheng	cheng	PROPN
dpc-4195	3	35	-	-	PUNCT
dpc-4195	3	36	che	che	PROPN
dpc-4195	3	37	eric	eric	PROPN
dpc-4195	3	38	lan1,3	lan1,3	PROPN
dpc-4195	3	39	1	1	NUM
dpc-4195	3	40	department	department	NOUN
dpc-4195	3	41	of	of	ADP
dpc-4195	3	42	dermatology	dermatology	NOUN
dpc-4195	3	43	,	,	PUNCT
dpc-4195	3	44	kaohsiung	kaohsiung	PROPN
dpc-4195	3	45	medical	medical	PROPN
dpc-4195	3	46	university	university	PROPN
dpc-4195	3	47	hospital	hospital	NOUN
dpc-4195	3	48	,	,	PUNCT
dpc-4195	3	49	kaohsiung	kaohsiung	PROPN
dpc-4195	3	50	medical	medical	PROPN
dpc-4195	3	51	university	university	PROPN
dpc-4195	3	52	,	,	PUNCT
dpc-4195	3	53	kaohsiung	kaohsiung	PROPN
dpc-4195	3	54	,	,	PUNCT
dpc-4195	3	55	taiwan	taiwan	PROPN
dpc-4195	3	56	2	2	NUM
dpc-4195	3	57	graduate	graduate	PROPN
dpc-4195	3	58	institute	institute	NOUN
dpc-4195	3	59	of	of	ADP
dpc-4195	3	60	clinical	clinical	ADJ
dpc-4195	3	61	medicine	medicine	NOUN
dpc-4195	3	62	,	,	PUNCT
dpc-4195	3	63	college	college	NOUN
dpc-4195	3	64	of	of	ADP
dpc-4195	3	65	medicine	medicine	NOUN
dpc-4195	3	66	,	,	PUNCT
dpc-4195	3	67	kaohsiung	kaohsiung	PROPN
dpc-4195	3	68	medical	medical	PROPN
dpc-4195	3	69	university	university	PROPN
dpc-4195	3	70	,	,	PUNCT
dpc-4195	3	71	kaohsiung	kaohsiung	PROPN
dpc-4195	3	72	,	,	PUNCT
dpc-4195	3	73	taiwan	taiwan	PROPN
dpc-4195	3	74	3	3	NUM
dpc-4195	3	75	department	department	PROPN
dpc-4195	3	76	of	of	ADP
dpc-4195	3	77	dermatology	dermatology	NOUN
dpc-4195	3	78	,	,	PUNCT
dpc-4195	3	79	college	college	NOUN
dpc-4195	3	80	of	of	ADP
dpc-4195	3	81	medicine	medicine	NOUN
dpc-4195	3	82	,	,	PUNCT
dpc-4195	3	83	kaohsiung	kaohsiung	PROPN
dpc-4195	3	84	medical	medical	PROPN
dpc-4195	3	85	university	university	PROPN
dpc-4195	3	86	,	,	PUNCT
dpc-4195	3	87	kaohsiung	kaohsiung	PROPN
dpc-4195	3	88	,	,	PUNCT
dpc-4195	3	89	taiwan	taiwan	PROPN
dpc-4195	3	90	key	key	ADJ
dpc-4195	3	91	words	word	NOUN
dpc-4195	3	92	:	:	PUNCT
dpc-4195	3	93	atopic	atopic	NOUN
dpc-4195	3	94	dermatitis	dermatitis	NOUN
dpc-4195	3	95	,	,	PUNCT
dpc-4195	3	96	upadacitinib	upadacitinib	NOUN
dpc-4195	3	97	,	,	PUNCT
dpc-4195	3	98	dosing	dosing	NOUN
dpc-4195	3	99	,	,	PUNCT
dpc-4195	3	100	effectiveness	effectiveness	NOUN
dpc-4195	3	101	,	,	PUNCT
dpc-4195	3	102	real	real	ADJ
dpc-4195	3	103	-	-	PUNCT
dpc-4195	3	104	world	world	NOUN
dpc-4195	3	105	citation	citation	NOUN
dpc-4195	3	106	:	:	PUNCT
dpc-4195	4	1	chen	chen	PROPN
dpc-4195	4	2	yy	yy	PROPN
dpc-4195	4	3	,	,	PUNCT
dpc-4195	4	4	chen	chen	PROPN
dpc-4195	4	5	ch	ch	PROPN
dpc-4195	4	6	,	,	PUNCT
dpc-4195	4	7	lan	lan	PROPN
dpc-4195	4	8	cce	cce	PROPN
dpc-4195	4	9	.	.	PUNCT
dpc-4195	5	1	real	real	ADJ
dpc-4195	5	2	-	-	PUNCT
dpc-4195	5	3	world	world	NOUN
dpc-4195	5	4	experience	experience	NOUN
dpc-4195	5	5	of	of	ADP
dpc-4195	5	6	upadacitinib	upadacitinib	NOUN
dpc-4195	5	7	dosing	dose	VERB
dpc-4195	5	8	reduction	reduction	NOUN
dpc-4195	5	9	in	in	ADP
dpc-4195	5	10	patients	patient	NOUN
dpc-4195	5	11	with	with	ADP
dpc-4195	5	12	moderate	moderate	ADJ
dpc-4195	5	13	atopic	atopic	NOUN
dpc-4195	5	14	dermatitis	dermatitis	NOUN
dpc-4195	5	15	:	:	PUNCT
dpc-4195	5	16	a	a	DET
dpc-4195	5	17	case	case	NOUN
dpc-4195	5	18	series	series	NOUN
dpc-4195	5	19	study	study	NOUN
dpc-4195	5	20	in	in	ADP
dpc-4195	5	21	taiwan	taiwan	PROPN
dpc-4195	5	22	.	.	PUNCT
dpc-4195	6	1	dermatol	dermatol	NOUN
dpc-4195	6	2	pract	pract	PROPN
dpc-4195	6	3	concept	concept	NOUN
dpc-4195	6	4	.	.	PUNCT
dpc-4195	7	1	2024;14(3):e2024186	2024;14(3):e2024186	NUM
dpc-4195	7	2	.	.	PUNCT
dpc-4195	7	3	doi	doi	NOUN
dpc-4195	7	4	:	:	PUNCT
dpc-4195	7	5	https://doi.org/10.5826/dpc.1403a186	https://doi.org/10.5826/dpc.1403a186	PROPN
dpc-4195	7	6	accepted	accept	VERB
dpc-4195	7	7	:	:	PUNCT
dpc-4195	7	8	march	march	PROPN
dpc-4195	7	9	3	3	NUM
dpc-4195	7	10	,	,	PUNCT
dpc-4195	7	11	2024	2024	NUM
dpc-4195	7	12	;	;	PUNCT
dpc-4195	7	13	published	publish	VERB
dpc-4195	7	14	:	:	PUNCT
dpc-4195	8	1	july	july	PROPN
dpc-4195	8	2	2024	2024	NUM
dpc-4195	8	3	copyright	copyright	NOUN
dpc-4195	8	4	:	:	PUNCT
dpc-4195	8	5	©	©	PROPN
dpc-4195	8	6	2024	2024	NUM
dpc-4195	8	7	chen	chen	PROPN
dpc-4195	8	8	et	et	PROPN
dpc-4195	8	9	al	al	PROPN
dpc-4195	8	10	.	.	PUNCT
dpc-4195	9	1	this	this	PRON
dpc-4195	9	2	is	be	AUX
dpc-4195	9	3	an	an	DET
dpc-4195	9	4	open	open	ADJ
dpc-4195	9	5	-	-	PUNCT
dpc-4195	9	6	access	access	NOUN
dpc-4195	9	7	article	article	NOUN
dpc-4195	9	8	distributed	distribute	VERB
dpc-4195	9	9	under	under	ADP
dpc-4195	9	10	the	the	DET
dpc-4195	9	11	terms	term	NOUN
dpc-4195	9	12	of	of	ADP
dpc-4195	9	13	the	the	DET
dpc-4195	9	14	creative	creative	ADJ
dpc-4195	9	15	commons	common	NOUN
dpc-4195	9	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4195	9	17	license	license	NOUN
dpc-4195	9	18	(	(	PUNCT
dpc-4195	9	19	by	by	ADP
dpc-4195	9	20	-	-	PUNCT
dpc-4195	9	21	nc-4.0	nc-4.0	NOUN
dpc-4195	9	22	)	)	PUNCT
dpc-4195	9	23	,	,	PUNCT
dpc-4195	9	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4195	9	25	,	,	PUNCT
dpc-4195	9	26	which	which	PRON
dpc-4195	9	27	permits	permit	VERB
dpc-4195	9	28	unrestricted	unrestricted	ADJ
dpc-4195	9	29	noncommercial	noncommercial	ADJ
dpc-4195	9	30	use	use	NOUN
dpc-4195	9	31	,	,	PUNCT
dpc-4195	9	32	distribution	distribution	NOUN
dpc-4195	9	33	,	,	PUNCT
dpc-4195	9	34	and	and	CCONJ
dpc-4195	9	35	reproduction	reproduction	NOUN
dpc-4195	9	36	in	in	ADP
dpc-4195	9	37	any	any	DET
dpc-4195	9	38	medium	medium	NOUN
dpc-4195	9	39	,	,	PUNCT
dpc-4195	9	40	provided	provide	VERB
dpc-4195	9	41	the	the	DET
dpc-4195	9	42	original	original	ADJ
dpc-4195	9	43	authors	author	NOUN
dpc-4195	9	44	and	and	CCONJ
dpc-4195	9	45	source	source	NOUN
dpc-4195	9	46	are	be	AUX
dpc-4195	9	47	credited	credit	VERB
dpc-4195	9	48	.	.	PUNCT
dpc-4195	10	1	funding	funding	NOUN
dpc-4195	10	2	:	:	PUNCT
dpc-4195	10	3	none	none	NOUN
dpc-4195	10	4	.	.	PUNCT
dpc-4195	11	1	competing	compete	VERB
dpc-4195	11	2	interests	interest	NOUN
dpc-4195	11	3	:	:	PUNCT
dpc-4195	11	4	none	none	NOUN
dpc-4195	11	5	.	.	PUNCT
dpc-4195	12	1	authorship	authorship	NOUN
dpc-4195	12	2	:	:	PUNCT
dpc-4195	12	3	all	all	DET
dpc-4195	12	4	authors	author	NOUN
dpc-4195	12	5	have	have	AUX
dpc-4195	12	6	contributed	contribute	VERB
dpc-4195	12	7	significantly	significantly	ADV
dpc-4195	12	8	to	to	ADP
dpc-4195	12	9	this	this	DET
dpc-4195	12	10	publication	publication	NOUN
dpc-4195	12	11	.	.	PUNCT
dpc-4195	13	1	corresponding	correspond	VERB
dpc-4195	13	2	author	author	NOUN
dpc-4195	13	3	:	:	PUNCT
dpc-4195	13	4	cheng	cheng	PROPN
dpc-4195	13	5	-	-	PUNCT
dpc-4195	13	6	che	che	PROPN
dpc-4195	13	7	eric	eric	PROPN
dpc-4195	13	8	lan	lan	PROPN
dpc-4195	13	9	,	,	PUNCT
dpc-4195	13	10	m.d	m.d	PROPN
dpc-4195	13	11	.	.	PROPN
dpc-4195	13	12	,	,	PUNCT
dpc-4195	13	13	ph.d	ph.d	PROPN
dpc-4195	13	14	.	.	PROPN
dpc-4195	13	15	,	,	PUNCT
dpc-4195	13	16	department	department	NOUN
dpc-4195	13	17	of	of	ADP
dpc-4195	13	18	dermatology	dermatology	NOUN
dpc-4195	13	19	,	,	PUNCT
dpc-4195	13	20	kaohsiung	kaohsiung	PROPN
dpc-4195	13	21	medical	medical	PROPN
dpc-4195	13	22	university	university	PROPN
dpc-4195	13	23	hospital	hospital	NOUN
dpc-4195	13	24	,	,	PUNCT
dpc-4195	13	25	kaohsiung	kaohsiung	PROPN
dpc-4195	13	26	medical	medical	PROPN
dpc-4195	13	27	university	university	PROPN
dpc-4195	13	28	,	,	PUNCT
dpc-4195	13	29	kaohsiung	kaohsiung	PROPN
dpc-4195	13	30	,	,	PUNCT
dpc-4195	13	31	taiwan	taiwan	PROPN
dpc-4195	13	32	.	.	PUNCT
dpc-4195	14	1	no.100	no.100	PROPN
dpc-4195	14	2	,	,	PUNCT
dpc-4195	14	3	tzyou	tzyou	PROPN
dpc-4195	14	4	1st	1st	PROPN
dpc-4195	14	5	rd	rd	PROPN
dpc-4195	14	6	.	.	PROPN
dpc-4195	14	7	,	,	PUNCT
dpc-4195	14	8	sanmin	sanmin	NOUN
dpc-4195	14	9	dist	dist	NOUN
dpc-4195	14	10	.	.	PUNCT
dpc-4195	14	11	,	,	PUNCT
dpc-4195	14	12	kaohsiung	kaohsiung	PROPN
dpc-4195	14	13	city	city	PROPN
dpc-4195	14	14	80756	80756	NUM
dpc-4195	14	15	,	,	PUNCT
dpc-4195	14	16	taiwan	taiwan	PROPN
dpc-4195	14	17	(	(	PUNCT
dpc-4195	14	18	r.o.c	r.o.c	PROPN
dpc-4195	14	19	.	.	PUNCT
dpc-4195	14	20	)	)	PUNCT
dpc-4195	15	1	tel	tel	ADP
dpc-4195	15	2	:	:	PUNCT
dpc-4195	15	3	+886	+886	NUM
dpc-4195	15	4	-	-	SYM
dpc-4195	15	5	7	7	NUM
dpc-4195	15	6	-	-	PUNCT
dpc-4195	15	7	3121101	3121101	NUM
dpc-4195	15	8	e	e	NOUN
dpc-4195	15	9	-	-	NOUN
dpc-4195	15	10	mail	mail	NOUN
dpc-4195	15	11	:	:	PUNCT
dpc-4195	15	12	laneric@cc.kmu.edu.tw	laneric@cc.kmu.edu.tw	NOUN
dpc-4195	15	13	introduction	introduction	PROPN
dpc-4195	15	14	oral	oral	ADJ
dpc-4195	15	15	janus	janus	PROPN
dpc-4195	15	16	kinase	kinase	PROPN
dpc-4195	15	17	1	1	NUM
dpc-4195	15	18	inhibitor	inhibitor	NOUN
dpc-4195	15	19	upadacitinib	upadacitinib	NOUN
dpc-4195	15	20	at	at	ADP
dpc-4195	15	21	15	15	NUM
dpc-4195	15	22	-	-	PUNCT
dpc-4195	15	23	mg	mg	NOUN
dpc-4195	15	24	and	and	CCONJ
dpc-4195	15	25	30	30	NUM
dpc-4195	15	26	-	-	PUNCT
dpc-4195	15	27	mg	mg	PROPN
dpc-4195	15	28	daily	daily	ADJ
dpc-4195	15	29	doses	dose	NOUN
dpc-4195	15	30	has	have	AUX
dpc-4195	15	31	been	be	AUX
dpc-4195	15	32	approved	approve	VERB
dpc-4195	15	33	for	for	ADP
dpc-4195	15	34	moderate	moderate	ADJ
dpc-4195	15	35	-	-	PUNCT
dpc-4195	15	36	tosevere	tosevere	NOUN
dpc-4195	15	37	atopic	atopic	NOUN
dpc-4195	15	38	dermatitis	dermatitis	NOUN
dpc-4195	15	39	(	(	PUNCT
dpc-4195	15	40	ad	ad	NOUN
dpc-4195	15	41	)	)	PUNCT
dpc-4195	15	42	.	.	PUNCT
dpc-4195	16	1	however	however	ADV
dpc-4195	16	2	,	,	PUNCT
dpc-4195	16	3	the	the	DET
dpc-4195	16	4	cost	cost	NOUN
dpc-4195	16	5	-	-	PUNCT
dpc-4195	16	6	effectiveness	effectiveness	NOUN
dpc-4195	16	7	of	of	ADP
dpc-4195	16	8	these	these	DET
dpc-4195	16	9	2	2	NUM
dpc-4195	16	10	regimens	regimen	NOUN
dpc-4195	16	11	is	be	AUX
dpc-4195	16	12	currently	currently	ADV
dpc-4195	16	13	unclear	unclear	ADJ
dpc-4195	16	14	.	.	PUNCT
dpc-4195	17	1	this	this	DET
dpc-4195	17	2	study	study	NOUN
dpc-4195	17	3	aimed	aim	VERB
dpc-4195	17	4	to	to	PART
dpc-4195	17	5	evaluate	evaluate	VERB
dpc-4195	17	6	the	the	DET
dpc-4195	17	7	impact	impact	NOUN
dpc-4195	17	8	of	of	ADP
dpc-4195	17	9	tapering	tapering	NOUN
dpc-4195	17	10	upadacitinib	upadacitinib	NOUN
dpc-4195	17	11	from	from	ADP
dpc-4195	17	12	30	30	NUM
dpc-4195	17	13	mg	mg	NOUN
dpc-4195	17	14	daily	daily	ADV
dpc-4195	17	15	to	to	ADP
dpc-4195	17	16	15	15	NUM
dpc-4195	17	17	mg	mg	NOUN
dpc-4195	17	18	daily	daily	ADV
dpc-4195	17	19	on	on	ADP
dpc-4195	17	20	disease	disease	NOUN
dpc-4195	17	21	control	control	NOUN
dpc-4195	17	22	in	in	ADP
dpc-4195	17	23	ad	ad	NOUN
dpc-4195	17	24	patients	patient	NOUN
dpc-4195	17	25	.	.	PUNCT
dpc-4195	18	1	we	we	PRON
dpc-4195	18	2	retrospectively	retrospectively	ADV
dpc-4195	18	3	recruited	recruit	VERB
dpc-4195	18	4	7	7	NUM
dpc-4195	18	5	adult	adult	NOUN
dpc-4195	18	6	ad	ad	NOUN
dpc-4195	18	7	patients	patient	NOUN
dpc-4195	18	8	who	who	PRON
dpc-4195	18	9	received	receive	VERB
dpc-4195	18	10	upadacitinib	upadacitinib	NOUN
dpc-4195	18	11	in	in	ADP
dpc-4195	18	12	the	the	DET
dpc-4195	18	13	dermatology	dermatology	NOUN
dpc-4195	18	14	department	department	PROPN
dpc-4195	18	15	of	of	ADP
dpc-4195	18	16	kaohsiung	kaohsiung	PROPN
dpc-4195	18	17	medical	medical	PROPN
dpc-4195	18	18	university	university	PROPN
dpc-4195	18	19	hospital	hospital	NOUN
dpc-4195	18	20	from	from	ADP
dpc-4195	18	21	2022	2022	NUM
dpc-4195	18	22	to	to	ADP
dpc-4195	18	23	2023	2023	NUM
dpc-4195	18	24	.	.	PUNCT
dpc-4195	19	1	this	this	DET
dpc-4195	19	2	study	study	NOUN
dpc-4195	19	3	was	be	AUX
dpc-4195	19	4	approved	approve	VERB
dpc-4195	19	5	by	by	ADP
dpc-4195	19	6	the	the	DET
dpc-4195	19	7	ethics	ethic	NOUN
dpc-4195	19	8	committee	committee	PROPN
dpc-4195	19	9	of	of	ADP
dpc-4195	19	10	kaohsiung	kaohsiung	PROPN
dpc-4195	19	11	medical	medical	PROPN
dpc-4195	19	12	university	university	PROPN
dpc-4195	19	13	hospital	hospital	NOUN
dpc-4195	19	14	kmuhirb	kmuhirb	VERB
dpc-4195	19	15	-e(i)-20230199	-e(i)-20230199	VERB
dpc-4195	19	16	.	.	PUNCT
dpc-4195	20	1	the	the	DET
dpc-4195	20	2	eczema	eczema	PROPN
dpc-4195	20	3	area	area	NOUN
dpc-4195	20	4	and	and	CCONJ
dpc-4195	20	5	severity	severity	NOUN
dpc-4195	20	6	index	index	NOUN
dpc-4195	20	7	(	(	PUNCT
dpc-4195	20	8	easi	easi	NOUN
dpc-4195	20	9	)	)	PUNCT
dpc-4195	20	10	and	and	CCONJ
dpc-4195	20	11	atopic	atopic	NOUN
dpc-4195	20	12	dermatitis	dermatitis	NOUN
dpc-4195	20	13	control	control	NOUN
dpc-4195	20	14	tool	tool	NOUN
dpc-4195	20	15	(	(	PUNCT
dpc-4195	20	16	adct	adct	PROPN
dpc-4195	20	17	)	)	PUNCT
dpc-4195	20	18	were	be	AUX
dpc-4195	20	19	utilized	utilize	VERB
dpc-4195	20	20	to	to	PART
dpc-4195	20	21	assess	assess	VERB
dpc-4195	20	22	treatment	treatment	NOUN
dpc-4195	20	23	responses	response	NOUN
dpc-4195	20	24	.	.	PUNCT
dpc-4195	21	1	adct	adct	PROPN
dpc-4195	21	2	is	be	AUX
dpc-4195	21	3	a	a	DET
dpc-4195	21	4	questionnaire	questionnaire	NOUN
dpc-4195	21	5	assessing	assess	VERB
dpc-4195	21	6	patientperceived	patientperceive	VERB
dpc-4195	21	7	control	control	NOUN
dpc-4195	21	8	of	of	ADP
dpc-4195	21	9	their	their	PRON
dpc-4195	21	10	ad	ad	NOUN
dpc-4195	22	1	[	[	X
dpc-4195	22	2	1	1	NUM
dpc-4195	22	3	]	]	PUNCT
dpc-4195	22	4	.	.	PUNCT
dpc-4195	23	1	case	case	NOUN
dpc-4195	23	2	presentation	presentation	NOUN
dpc-4195	23	3	seven	seven	NUM
dpc-4195	23	4	ad	ad	NOUN
dpc-4195	23	5	patients	patient	NOUN
dpc-4195	23	6	had	have	VERB
dpc-4195	23	7	a	a	DET
dpc-4195	23	8	baseline	baseline	ADJ
dpc-4195	23	9	easi	easi	NOUN
dpc-4195	23	10	of	of	ADP
dpc-4195	23	11	16.6	16.6	NUM
dpc-4195	23	12	±	±	NUM
dpc-4195	23	13	3.0	3.0	NUM
dpc-4195	23	14	and	and	CCONJ
dpc-4195	23	15	adct	adct	PROPN
dpc-4195	23	16	of	of	ADP
dpc-4195	23	17	13.9±4.5	13.9±4.5	NUM
dpc-4195	23	18	before	before	ADP
dpc-4195	23	19	upadacitinib	upadacitinib	NOUN
dpc-4195	23	20	treatment	treatment	NOUN
dpc-4195	23	21	(	(	PUNCT
dpc-4195	23	22	table	table	NOUN
dpc-4195	23	23	1	1	NUM
dpc-4195	23	24	)	)	PUNCT
dpc-4195	23	25	.	.	PUNCT
dpc-4195	24	1	these	these	DET
dpc-4195	24	2	patients	patient	NOUN
dpc-4195	24	3	received	receive	VERB
dpc-4195	24	4	upadacitinib	upadacitinib	NOUN
dpc-4195	24	5	30	30	NUM
dpc-4195	24	6	mg	mg	NOUN
dpc-4195	24	7	daily	daily	ADJ
dpc-4195	24	8	treatment	treatment	NOUN
dpc-4195	24	9	for	for	ADP
dpc-4195	24	10	the	the	DET
dpc-4195	24	11	initial	initial	ADJ
dpc-4195	24	12	two	two	NUM
dpc-4195	24	13	months	month	NOUN
dpc-4195	24	14	(	(	PUNCT
dpc-4195	24	15	figure	figure	NOUN
dpc-4195	24	16	1	1	NUM
dpc-4195	24	17	)	)	PUNCT
dpc-4195	24	18	.	.	PUNCT
dpc-4195	25	1	upadacitinib	upadacitinib	NOUN
dpc-4195	25	2	30	30	NUM
dpc-4195	25	3	mg	mg	NOUN
dpc-4195	25	4	daily	daily	ADV
dpc-4195	25	5	showed	show	VERB
dpc-4195	25	6	a	a	DET
dpc-4195	25	7	rapid	rapid	ADJ
dpc-4195	25	8	effect	effect	NOUN
dpc-4195	25	9	with	with	ADP
dpc-4195	25	10	a	a	DET
dpc-4195	25	11	mean	mean	ADJ
dpc-4195	25	12	easi	easi	NOUN
dpc-4195	25	13	being	be	AUX
dpc-4195	25	14	reduced	reduce	VERB
dpc-4195	25	15	to	to	ADP
dpc-4195	25	16	2.7	2.7	NUM
dpc-4195	25	17	±	±	NUM
dpc-4195	25	18	3.4	3.4	NUM
dpc-4195	25	19	and	and	CCONJ
dpc-4195	25	20	adct	adct	VERB
dpc-4195	25	21	to	to	ADP
dpc-4195	25	22	3.7	3.7	NUM
dpc-4195	25	23	±	±	NUM
dpc-4195	25	24	4.2	4.2	NUM
dpc-4195	25	25	after	after	ADP
dpc-4195	25	26	2	2	NUM
dpc-4195	25	27	months	month	NOUN
dpc-4195	25	28	.	.	PUNCT
dpc-4195	26	1	notably	notably	ADV
dpc-4195	26	2	,	,	PUNCT
dpc-4195	26	3	6	6	NUM
dpc-4195	26	4	patients	patient	NOUN
dpc-4195	26	5	achieved	achieve	VERB
dpc-4195	26	6	easi-90	easi-90	NOUN
dpc-4195	26	7	(	(	PUNCT
dpc-4195	26	8	≥	≥	NUM
dpc-4195	26	9	90	90	NUM
dpc-4195	26	10	%	%	NOUN
dpc-4195	26	11	improvement	improvement	NOUN
dpc-4195	26	12	from	from	ADP
dpc-4195	26	13	baseline	baseline	NOUN
dpc-4195	26	14	)	)	PUNCT
dpc-4195	26	15	within	within	ADP
dpc-4195	26	16	2	2	NUM
dpc-4195	26	17	months	month	NOUN
dpc-4195	26	18	with	with	ADP
dpc-4195	26	19	a	a	DET
dpc-4195	26	20	mean	mean	NOUN
dpc-4195	26	21	easi	easi	PROPN
dpc-4195	26	22	1.5±1.3	1.5±1.3	NUM
dpc-4195	26	23	(	(	PUNCT
dpc-4195	26	24	figure	figure	NOUN
dpc-4195	26	25	2a	2a	NUM
dpc-4195	26	26	)	)	PUNCT
dpc-4195	26	27	.	.	PUNCT
dpc-4195	27	1	their	their	PRON
dpc-4195	27	2	dosing	dosing	NOUN
dpc-4195	27	3	was	be	AUX
dpc-4195	27	4	reduced	reduce	VERB
dpc-4195	27	5	to	to	ADP
dpc-4195	27	6	15	15	NUM
dpc-4195	27	7	mg	mg	NOUN
dpc-4195	27	8	daily	daily	ADV
dpc-4195	27	9	in	in	ADP
dpc-4195	27	10	the	the	DET
dpc-4195	27	11	following	follow	VERB
dpc-4195	27	12	2	2	NUM
dpc-4195	27	13	months	month	NOUN
dpc-4195	27	14	.	.	PUNCT
dpc-4195	28	1	step	step	NOUN
dpc-4195	28	2	-	-	PUNCT
dpc-4195	28	3	down	down	ADP
dpc-4195	28	4	treatment	treatment	NOUN
dpc-4195	28	5	maintained	maintain	VERB
dpc-4195	28	6	an	an	DET
dpc-4195	28	7	acceptable	acceptable	ADJ
dpc-4195	28	8	therapeutic	therapeutic	ADJ
dpc-4195	28	9	efficacy	efficacy	NOUN
dpc-4195	28	10	in	in	ADP
dpc-4195	28	11	these	these	DET
dpc-4195	28	12	patients	patient	NOUN
dpc-4195	28	13	(	(	PUNCT
dpc-4195	28	14	easi	easi	NOUN
dpc-4195	28	15	1.7±1.2	1.7±1.2	NUM
dpc-4195	28	16	after	after	ADP
dpc-4195	28	17	4	4	NUM
dpc-4195	28	18	months	month	NOUN
dpc-4195	28	19	)	)	PUNCT
dpc-4195	28	20	,	,	PUNCT
dpc-4195	28	21	whereas	whereas	SCONJ
dpc-4195	28	22	step	step	NOUN
dpc-4195	28	23	-	-	PUNCT
dpc-4195	28	24	down	down	ADP
dpc-4195	28	25	treatment	treatment	NOUN
dpc-4195	28	26	led	lead	VERB
dpc-4195	28	27	to	to	ADP
dpc-4195	28	28	slightly	slightly	ADV
dpc-4195	28	29	increased	increase	VERB
dpc-4195	28	30	adct	adct	ADJ
dpc-4195	28	31	scores	score	NOUN
dpc-4195	28	32	(	(	PUNCT
dpc-4195	28	33	3.8±3.1	3.8±3.1	NUM
dpc-4195	28	34	after	after	ADP
dpc-4195	28	35	4	4	NUM
dpc-4195	28	36	months	month	NOUN
dpc-4195	28	37	)	)	PUNCT
dpc-4195	28	38	(	(	PUNCT
dpc-4195	28	39	figure	figure	NOUN
dpc-4195	28	40	2b	2b	NOUN
dpc-4195	28	41	)	)	PUNCT
dpc-4195	28	42	.	.	PUNCT
dpc-4195	29	1	after	after	ADP
dpc-4195	29	2	discontinuation	discontinuation	NOUN
dpc-4195	29	3	of	of	ADP
dpc-4195	29	4	upadacitinib	upadacitinib	NOUN
dpc-4195	29	5	,	,	PUNCT
dpc-4195	29	6	5/7	5/7	NUM
dpc-4195	29	7	patients	patient	NOUN
dpc-4195	29	8	suffered	suffer	VERB
dpc-4195	29	9	from	from	ADP
dpc-4195	29	10	rapid	rapid	ADJ
dpc-4195	29	11	disease	disease	NOUN
dpc-4195	29	12	flare	flare	VERB
dpc-4195	29	13	within	within	ADP
dpc-4195	29	14	1	1	NUM
dpc-4195	29	15	month	month	NOUN
dpc-4195	29	16	.	.	PUNCT
dpc-4195	30	1	2	2	NUM
dpc-4195	30	2	research	research	NOUN
dpc-4195	30	3	letter	letter	NOUN
dpc-4195	30	4	|	|	ADV
dpc-4195	30	5	dermatol	dermatol	ADJ
dpc-4195	30	6	pract	pract	NOUN
dpc-4195	30	7	concept	concept	NOUN
dpc-4195	30	8	.	.	PUNCT
dpc-4195	31	1	2024;14(3):e2024186	2024;14(3):e2024186	NUM
dpc-4195	31	2	table	table	NOUN
dpc-4195	31	3	1	1	NUM
dpc-4195	31	4	.	.	PUNCT
dpc-4195	31	5	demographic	demographic	ADJ
dpc-4195	31	6	characteristics	characteristic	NOUN
dpc-4195	31	7	of	of	ADP
dpc-4195	31	8	included	include	VERB
dpc-4195	31	9	atopic	atopic	NOUN
dpc-4195	31	10	dermatitis	dermatitis	NOUN
dpc-4195	31	11	patients	patient	NOUN
dpc-4195	31	12	and	and	CCONJ
dpc-4195	31	13	their	their	PRON
dpc-4195	31	14	disease	disease	NOUN
dpc-4195	31	15	severity	severity	NOUN
dpc-4195	31	16	at	at	ADP
dpc-4195	31	17	baseline	baseline	NOUN
dpc-4195	31	18	and	and	CCONJ
dpc-4195	31	19	after	after	ADP
dpc-4195	31	20	upadacitinib	upadacitinib	NOUN
dpc-4195	31	21	treatment	treatment	NOUN
dpc-4195	31	22	patient	patient	NOUN
dpc-4195	32	1	no	no	INTJ
dpc-4195	32	2	.	.	NOUN
dpc-4195	32	3	1	1	NUM
dpc-4195	32	4	2	2	NUM
dpc-4195	32	5	3	3	NUM
dpc-4195	32	6	4	4	NUM
dpc-4195	32	7	5	5	NUM
dpc-4195	32	8	6	6	NUM
dpc-4195	32	9	7	7	NUM
dpc-4195	32	10	demographic	demographic	ADJ
dpc-4195	32	11	characteristics	characteristic	NOUN
dpc-4195	32	12	gender	gender	NOUN
dpc-4195	33	1	f	f	PROPN
dpc-4195	34	1	f	f	PROPN
dpc-4195	34	2	f	f	PROPN
dpc-4195	35	1	f	f	PROPN
dpc-4195	35	2	m	m	VERB
dpc-4195	35	3	m	m	VERB
dpc-4195	35	4	m	m	VERB
dpc-4195	35	5	age	age	NOUN
dpc-4195	35	6	(	(	PUNCT
dpc-4195	35	7	y	y	NOUN
dpc-4195	35	8	/	/	SYM
dpc-4195	35	9	o	o	NOUN
dpc-4195	35	10	)	)	PUNCT
dpc-4195	35	11	20	20	NUM
dpc-4195	35	12	30	30	NUM
dpc-4195	35	13	25	25	NUM
dpc-4195	35	14	22	22	NUM
dpc-4195	35	15	32	32	NUM
dpc-4195	35	16	34	34	NUM
dpc-4195	35	17	30	30	NUM
dpc-4195	35	18	ige	ige	PROPN
dpc-4195	35	19	(	(	PUNCT
dpc-4195	35	20	iu	iu	PROPN
dpc-4195	35	21	/	/	SYM
dpc-4195	35	22	ml	ml	NOUN
dpc-4195	35	23	)	)	PUNCT
dpc-4195	35	24	1508	1508	NUM
dpc-4195	35	25	334	334	NUM
dpc-4195	35	26	57.1	57.1	NUM
dpc-4195	35	27	1526	1526	NUM
dpc-4195	35	28	17508	17508	NUM
dpc-4195	35	29	1931	1931	NUM
dpc-4195	35	30	228	228	NUM
dpc-4195	35	31	weight	weight	NOUN
dpc-4195	35	32	(	(	PUNCT
dpc-4195	35	33	kg	kg	NOUN
dpc-4195	35	34	)	)	PUNCT
dpc-4195	35	35	61	61	NUM
dpc-4195	35	36	67	67	NUM
dpc-4195	35	37	49	49	NUM
dpc-4195	35	38	52	52	NUM
dpc-4195	35	39	78	78	NUM
dpc-4195	35	40	77	77	NUM
dpc-4195	35	41	69	69	NUM
dpc-4195	35	42	previous	previous	ADJ
dpc-4195	35	43	treatment	treatment	NOUN
dpc-4195	35	44	mtx	mtx	NOUN
dpc-4195	35	45	mtx	mtx	NOUN
dpc-4195	35	46	uvb	uvb	ADJ
dpc-4195	35	47	uvb	uvb	ADJ
dpc-4195	35	48	systemic	systemic	ADJ
dpc-4195	35	49	cs	cs	PROPN
dpc-4195	35	50	uvb	uvb	PROPN
dpc-4195	35	51	systemic	systemic	PROPN
dpc-4195	35	52	cs	cs	PROPN
dpc-4195	35	53	disease	disease	PROPN
dpc-4195	35	54	severity	severity	NOUN
dpc-4195	35	55	baseline	baseline	VERB
dpc-4195	35	56	easi	easi	NOUN
dpc-4195	35	57	19.8	19.8	NUM
dpc-4195	35	58	18.2	18.2	NUM
dpc-4195	35	59	14.1	14.1	NUM
dpc-4195	35	60	16.1	16.1	NUM
dpc-4195	35	61	17.4	17.4	NUM
dpc-4195	35	62	11.3	11.3	NUM
dpc-4195	35	63	19.4	19.4	NUM
dpc-4195	35	64	baseline	baseline	NOUN
dpc-4195	35	65	adct	adct	VERB
dpc-4195	35	66	14	14	NUM
dpc-4195	35	67	17	17	NUM
dpc-4195	35	68	16	16	NUM
dpc-4195	35	69	8	8	NUM
dpc-4195	35	70	10	10	NUM
dpc-4195	35	71	11	11	NUM
dpc-4195	35	72	21	21	NUM
dpc-4195	35	73	response	response	NOUN
dpc-4195	35	74	to	to	PART
dpc-4195	35	75	upa	upa	VERB
dpc-4195	35	76	easi	easi	NOUN
dpc-4195	35	77	post	post	NOUN
dpc-4195	35	78	2	2	NUM
dpc-4195	35	79	months	month	NOUN
dpc-4195	35	80	30mg	30mg	NUM
dpc-4195	35	81	/	/	SYM
dpc-4195	35	82	day	day	NOUN
dpc-4195	35	83	(	(	PUNCT
dpc-4195	35	84	δeasi)a	δeasi)a	PROPN
dpc-4195	35	85	1.9	1.9	NUM
dpc-4195	35	86	(	(	PUNCT
dpc-4195	35	87	90.4	90.4	NUM
dpc-4195	35	88	)	)	PUNCT
dpc-4195	35	89	1.8	1.8	NUM
dpc-4195	35	90	(	(	PUNCT
dpc-4195	35	91	90.1	90.1	NUM
dpc-4195	35	92	)	)	PUNCT
dpc-4195	35	93	0.4	0.4	NUM
dpc-4195	35	94	(	(	PUNCT
dpc-4195	35	95	97.2	97.2	NUM
dpc-4195	35	96	)	)	PUNCT
dpc-4195	35	97	1.4	1.4	NUM
dpc-4195	35	98	(	(	PUNCT
dpc-4195	35	99	91.3	91.3	NUM
dpc-4195	35	100	)	)	PUNCT
dpc-4195	35	101	9.9	9.9	NUM
dpc-4195	35	102	(	(	PUNCT
dpc-4195	35	103	43.1	43.1	NUM
dpc-4195	35	104	)	)	PUNCT
dpc-4195	35	105	0	0	NUM
dpc-4195	36	1	(	(	PUNCT
dpc-4195	36	2	100	100	NUM
dpc-4195	36	3	)	)	PUNCT
dpc-4195	36	4	1.9	1.9	NUM
dpc-4195	36	5	(	(	PUNCT
dpc-4195	36	6	90.2	90.2	NUM
dpc-4195	36	7	)	)	PUNCT
dpc-4195	36	8	easi	easi	NOUN
dpc-4195	36	9	post	post	NOUN
dpc-4195	36	10	2	2	NUM
dpc-4195	36	11	months	month	NOUN
dpc-4195	36	12	15mg	15mg	NUM
dpc-4195	36	13	/	/	SYM
dpc-4195	36	14	day	day	NOUN
dpc-4195	36	15	(	(	PUNCT
dpc-4195	36	16	δeasi	δeasi	PROPN
dpc-4195	36	17	)	)	PUNCT
dpc-4195	36	18	2.0	2.0	NUM
dpc-4195	36	19	(	(	PUNCT
dpc-4195	36	20	89.9	89.9	NUM
dpc-4195	36	21	)	)	PUNCT
dpc-4195	36	22	2.5	2.5	NUM
dpc-4195	36	23	(	(	PUNCT
dpc-4195	36	24	86.3	86.3	NUM
dpc-4195	36	25	)	)	PUNCT
dpc-4195	36	26	0.4	0.4	NUM
dpc-4195	36	27	(	(	PUNCT
dpc-4195	36	28	97.2	97.2	NUM
dpc-4195	36	29	)	)	PUNCT
dpc-4195	36	30	2.6	2.6	NUM
dpc-4195	36	31	(	(	PUNCT
dpc-4195	36	32	83.9	83.9	NUM
dpc-4195	36	33	)	)	PUNCT
dpc-4195	36	34	8.9b	8.9b	PROPN
dpc-4195	36	35	(	(	PUNCT
dpc-4195	36	36	48.9	48.9	NUM
dpc-4195	36	37	)	)	PUNCT
dpc-4195	36	38	0	0	NUM
dpc-4195	37	1	(	(	PUNCT
dpc-4195	37	2	100	100	NUM
dpc-4195	37	3	)	)	PUNCT
dpc-4195	37	4	2.8	2.8	NUM
dpc-4195	37	5	(	(	PUNCT
dpc-4195	37	6	85.5	85.5	NUM
dpc-4195	37	7	)	)	PUNCT
dpc-4195	37	8	dosing	dose	VERB
dpc-4195	37	9	reduction	reduction	NOUN
dpc-4195	37	10	y	y	PROPN
dpc-4195	38	1	y	y	PROPN
dpc-4195	38	2	y	y	PROPN
dpc-4195	38	3	y	y	PROPN
dpc-4195	38	4	n	n	CCONJ
dpc-4195	38	5	y	y	PROPN
dpc-4195	38	6	y	y	PROPN
dpc-4195	38	7	adct	adct	VERB
dpc-4195	38	8	post	post	NOUN
dpc-4195	38	9	2	2	NUM
dpc-4195	38	10	months	month	NOUN
dpc-4195	38	11	30mg	30mg	NUM
dpc-4195	38	12	/	/	SYM
dpc-4195	38	13	day	day	NOUN
dpc-4195	38	14	1	1	NUM
dpc-4195	38	15	4	4	NUM
dpc-4195	38	16	0	0	NUM
dpc-4195	38	17	2	2	NUM
dpc-4195	38	18	10	10	NUM
dpc-4195	38	19	0	0	NUM
dpc-4195	38	20	9	9	NUM
dpc-4195	38	21	adct	adct	ADJ
dpc-4195	38	22	post	post	NOUN
dpc-4195	38	23	2	2	NUM
dpc-4195	38	24	months	month	NOUN
dpc-4195	38	25	15mg	15mg	ADJ
dpc-4195	38	26	/	/	SYM
dpc-4195	38	27	day	day	NOUN
dpc-4195	38	28	3	3	NUM
dpc-4195	38	29	7	7	NUM
dpc-4195	38	30	2	2	NUM
dpc-4195	38	31	3	3	NUM
dpc-4195	38	32	8b	8b	NUM
dpc-4195	38	33	0	0	NUM
dpc-4195	38	34	8	8	NUM
dpc-4195	38	35	discontinuation	discontinuation	NOUN
dpc-4195	38	36	of	of	ADP
dpc-4195	38	37	upa	upa	ADJ
dpc-4195	38	38	easi	easi	NOUN
dpc-4195	38	39	score	score	NOUN
dpc-4195	38	40	c	c	PROPN
dpc-4195	38	41	2.65	2.65	NUM
dpc-4195	38	42	9.8	9.8	NUM
dpc-4195	38	43	0.8	0.8	NUM
dpc-4195	38	44	2.6	2.6	NUM
dpc-4195	38	45	14.7	14.7	NUM
dpc-4195	38	46	0	0	NUM
dpc-4195	38	47	12.0	12.0	NUM
dpc-4195	38	48	adct	adct	PROPN
dpc-4195	38	49	score	score	NOUN
dpc-4195	38	50	c	c	PROPN
dpc-4195	38	51	13	13	NUM
dpc-4195	38	52	13	13	NUM
dpc-4195	38	53	10	10	NUM
dpc-4195	38	54	1	1	NUM
dpc-4195	38	55	16	16	NUM
dpc-4195	38	56	0	0	NUM
dpc-4195	38	57	22	22	NUM
dpc-4195	38	58	treatment	treatment	NOUN
dpc-4195	38	59	required	require	VERB
dpc-4195	38	60	mtx	mtx	NOUN
dpc-4195	38	61	mtx+uvb	mtx+uvb	PROPN
dpc-4195	38	62	aza	aza	PROPN
dpc-4195	38	63	anh	anh	PROPN
dpc-4195	38	64	csa	csa	PROPN
dpc-4195	38	65	anh	anh	PROPN
dpc-4195	38	66	upa	upa	PROPN
dpc-4195	39	1	+	+	CCONJ
dpc-4195	39	2	uvb	uvb	ADJ
dpc-4195	39	3	aδeasi	aδeasi	NOUN
dpc-4195	39	4	:	:	PUNCT
dpc-4195	39	5	percentage	percentage	NOUN
dpc-4195	39	6	change	change	NOUN
dpc-4195	39	7	in	in	ADP
dpc-4195	39	8	easi	easi	NOUN
dpc-4195	39	9	score	score	NOUN
dpc-4195	39	10	as	as	SCONJ
dpc-4195	39	11	compared	compare	VERB
dpc-4195	39	12	with	with	ADP
dpc-4195	39	13	baseline	baseline	NOUN
dpc-4195	39	14	easi	easi	NOUN
dpc-4195	39	15	.	.	PUNCT
dpc-4195	40	1	bresponse	bresponse	NOUN
dpc-4195	40	2	to	to	ADP
dpc-4195	40	3	additional	additional	ADJ
dpc-4195	40	4	1	1	NUM
dpc-4195	40	5	month	month	NOUN
dpc-4195	40	6	of	of	ADP
dpc-4195	40	7	30mg	30mg	NUM
dpc-4195	40	8	/	/	SYM
dpc-4195	40	9	day	day	NOUN
dpc-4195	40	10	treatment	treatment	NOUN
dpc-4195	40	11	due	due	ADP
dpc-4195	40	12	to	to	ADP
dpc-4195	40	13	not	not	PART
dpc-4195	40	14	achieving	achieve	VERB
dpc-4195	40	15	easi-90	easi-90	NOUN
dpc-4195	40	16	.	.	PUNCT
dpc-4195	40	17	cwithin	cwithin	PROPN
dpc-4195	40	18	1	1	NUM
dpc-4195	40	19	month	month	NOUN
dpc-4195	40	20	(	(	PUNCT
dpc-4195	40	21	before	before	ADP
dpc-4195	40	22	restart	restart	NOUN
dpc-4195	40	23	of	of	ADP
dpc-4195	40	24	systemic	systemic	ADJ
dpc-4195	40	25	treatment	treatment	NOUN
dpc-4195	40	26	for	for	ADP
dpc-4195	40	27	ad	ad	NOUN
dpc-4195	40	28	)	)	PUNCT
dpc-4195	40	29	.	.	PUNCT
dpc-4195	41	1	adct	adct	VERB
dpc-4195	41	2	=	=	SYM
dpc-4195	41	3	atopic	atopic	NOUN
dpc-4195	41	4	dermatitis	dermatitis	NOUN
dpc-4195	41	5	control	control	NOUN
dpc-4195	41	6	tool	tool	NOUN
dpc-4195	41	7	;	;	PUNCT
dpc-4195	41	8	anh	anh	NOUN
dpc-4195	41	9	=	=	SYM
dpc-4195	41	10	antihistamine	antihistamine	PROPN
dpc-4195	41	11	;	;	PUNCT
dpc-4195	41	12	aza	aza	NOUN
dpc-4195	41	13	=	=	SYM
dpc-4195	41	14	azathioprine	azathioprine	NOUN
dpc-4195	41	15	;	;	PUNCT
dpc-4195	41	16	cs	cs	PROPN
dpc-4195	41	17	=	=	SYM
dpc-4195	41	18	corticosteroids	corticosteroid	NOUN
dpc-4195	41	19	;	;	PUNCT
dpc-4195	41	20	csa	csa	PROPN
dpc-4195	41	21	=	=	PROPN
dpc-4195	41	22	cyclosporine	cyclosporine	PROPN
dpc-4195	41	23	;	;	PUNCT
dpc-4195	41	24	easi	easi	ADJ
dpc-4195	41	25	=	=	SYM
dpc-4195	41	26	eczema	eczema	NOUN
dpc-4195	41	27	area	area	NOUN
dpc-4195	41	28	and	and	CCONJ
dpc-4195	41	29	severity	severity	NOUN
dpc-4195	41	30	index	index	NOUN
dpc-4195	41	31	;	;	PUNCT
dpc-4195	41	32	mtx	mtx	NOUN
dpc-4195	41	33	=	=	PUNCT
dpc-4195	41	34	methotrexate	methotrexate	NOUN
dpc-4195	41	35	;	;	PUNCT
dpc-4195	41	36	upa	upa	NOUN
dpc-4195	41	37	=	=	PUNCT
dpc-4195	41	38	upadacitinib	upadacitinib	NOUN
dpc-4195	41	39	;	;	PUNCT
dpc-4195	41	40	uvb	uvb	ADJ
dpc-4195	41	41	=	=	PUNCT
dpc-4195	41	42	narrow	narrow	ADJ
dpc-4195	41	43	-	-	PUNCT
dpc-4195	41	44	band	band	NOUN
dpc-4195	41	45	uvb	uvb	ADJ
dpc-4195	41	46	.	.	PROPN
dpc-4195	41	47	figure	figure	NOUN
dpc-4195	41	48	1	1	NUM
dpc-4195	41	49	.	.	PUNCT
dpc-4195	42	1	our	our	PRON
dpc-4195	42	2	department	department	NOUN
dpc-4195	42	3	protocol	protocol	NOUN
dpc-4195	42	4	and	and	CCONJ
dpc-4195	42	5	dosing	dose	VERB
dpc-4195	42	6	regimen	regiman	NOUN
dpc-4195	42	7	for	for	ADP
dpc-4195	42	8	patients	patient	NOUN
dpc-4195	42	9	with	with	ADP
dpc-4195	42	10	moderate	moderate	ADJ
dpc-4195	42	11	-	-	PUNCT
dpc-4195	42	12	to	to	ADP
dpc-4195	42	13	-	-	PUNCT
dpc-4195	42	14	severe	severe	ADJ
dpc-4195	42	15	atopic	atopic	NOUN
dpc-4195	42	16	dermatitis	dermatitis	NOUN
dpc-4195	42	17	receiving	receive	VERB
dpc-4195	42	18	upadacitinib	upadacitinib	NOUN
dpc-4195	42	19	.	.	PUNCT
dpc-4195	43	1	discussion	discussion	NOUN
dpc-4195	43	2	previous	previous	ADJ
dpc-4195	43	3	large	large	ADJ
dpc-4195	43	4	-	-	PUNCT
dpc-4195	43	5	scale	scale	NOUN
dpc-4195	43	6	clinical	clinical	ADJ
dpc-4195	43	7	trials	trial	NOUN
dpc-4195	43	8	showed	show	VERB
dpc-4195	43	9	easi-90	easi-90	NOUN
dpc-4195	43	10	response	response	NOUN
dpc-4195	43	11	rate	rate	NOUN
dpc-4195	43	12	of	of	ADP
dpc-4195	43	13	upadacitinib	upadacitinib	NOUN
dpc-4195	43	14	30	30	NUM
dpc-4195	43	15	mg	mg	NOUN
dpc-4195	43	16	daily	daily	PROPN
dpc-4195	43	17	dose	dose	NOUN
dpc-4195	43	18	was	be	AUX
dpc-4195	43	19	about	about	ADV
dpc-4195	43	20	60	60	NUM
dpc-4195	43	21	-	-	SYM
dpc-4195	43	22	61	61	NUM
dpc-4195	43	23	%	%	NOUN
dpc-4195	43	24	in	in	ADP
dpc-4195	43	25	patients	patient	NOUN
dpc-4195	43	26	with	with	ADP
dpc-4195	43	27	moderate	moderate	ADJ
dpc-4195	43	28	-	-	PUNCT
dpc-4195	43	29	to	to	ADP
dpc-4195	43	30	-	-	PUNCT
dpc-4195	43	31	severe	severe	ADJ
dpc-4195	43	32	ad	ad	NOUN
dpc-4195	43	33	at	at	ADP
dpc-4195	43	34	week	week	NOUN
dpc-4195	43	35	8	8	NUM
dpc-4195	44	1	[	[	X
dpc-4195	44	2	2	2	NUM
dpc-4195	44	3	-	-	SYM
dpc-4195	44	4	4	4	NUM
dpc-4195	44	5	]	]	PUNCT
dpc-4195	44	6	.	.	PUNCT
dpc-4195	45	1	meanwhile	meanwhile	ADV
dpc-4195	45	2	,	,	PUNCT
dpc-4195	45	3	easi-90	easi-90	NOUN
dpc-4195	45	4	response	response	NOUN
dpc-4195	45	5	rates	rate	NOUN
dpc-4195	45	6	in	in	ADP
dpc-4195	45	7	patients	patient	NOUN
dpc-4195	45	8	receiving	receive	VERB
dpc-4195	45	9	15	15	NUM
dpc-4195	45	10	mg	mg	NOUN
dpc-4195	45	11	was	be	AUX
dpc-4195	45	12	36	36	NUM
dpc-4195	45	13	%	%	NOUN
dpc-4195	45	14	at	at	ADP
dpc-4195	45	15	week	week	NOUN
dpc-4195	45	16	8	8	NUM
dpc-4195	45	17	and	and	CCONJ
dpc-4195	45	18	43%-48	43%-48	NUM
dpc-4195	45	19	%	%	NOUN
dpc-4195	45	20	at	at	ADP
dpc-4195	45	21	week	week	NOUN
dpc-4195	45	22	16	16	NUM
dpc-4195	46	1	[	[	X
dpc-4195	46	2	2,3	2,3	NUM
dpc-4195	46	3	]	]	PUNCT
dpc-4195	46	4	.	.	PUNCT
dpc-4195	47	1	therefore	therefore	ADV
dpc-4195	47	2	,	,	PUNCT
dpc-4195	47	3	upadacitinib	upadacitinib	NOUN
dpc-4195	47	4	30	30	NUM
dpc-4195	47	5	-	-	PUNCT
dpc-4195	47	6	mg	mg	PROPN
dpc-4195	47	7	daily	daily	PROPN
dpc-4195	47	8	dose	dose	NOUN
dpc-4195	47	9	was	be	AUX
dpc-4195	47	10	used	use	VERB
dpc-4195	47	11	initially	initially	ADV
dpc-4195	47	12	to	to	PART
dpc-4195	47	13	achieve	achieve	VERB
dpc-4195	47	14	rapid	rapid	ADJ
dpc-4195	47	15	disease	disease	NOUN
dpc-4195	47	16	control	control	NOUN
dpc-4195	47	17	.	.	PUNCT
dpc-4195	48	1	then	then	ADV
dpc-4195	48	2	,	,	PUNCT
dpc-4195	48	3	this	this	DET
dpc-4195	48	4	study	study	NOUN
dpc-4195	48	5	demonstrated	demonstrate	VERB
dpc-4195	48	6	the	the	DET
dpc-4195	48	7	impacts	impact	NOUN
dpc-4195	48	8	of	of	ADP
dpc-4195	48	9	dose	dose	NOUN
dpc-4195	48	10	reduction	reduction	NOUN
dpc-4195	48	11	on	on	ADP
dpc-4195	48	12	skin	skin	NOUN
dpc-4195	48	13	lesional	lesional	ADJ
dpc-4195	48	14	severity	severity	NOUN
dpc-4195	48	15	and	and	CCONJ
dpc-4195	48	16	subjective	subjective	ADJ
dpc-4195	48	17	symptoms	symptom	NOUN
dpc-4195	48	18	in	in	ADP
dpc-4195	48	19	patients	patient	NOUN
dpc-4195	48	20	receiving	receive	VERB
dpc-4195	48	21	upadacitinib	upadacitinib	NOUN
dpc-4195	48	22	.	.	PUNCT
dpc-4195	49	1	tapering	taper	VERB
dpc-4195	49	2	upadacitinib	upadacitinib	NOUN
dpc-4195	49	3	dosage	dosage	NOUN
dpc-4195	49	4	in	in	ADP
dpc-4195	49	5	patients	patient	NOUN
dpc-4195	49	6	achieving	achieve	VERB
dpc-4195	49	7	easi-90	easi-90	NOUN
dpc-4195	49	8	led	lead	VERB
dpc-4195	49	9	to	to	ADP
dpc-4195	49	10	persistent	persistent	ADJ
dpc-4195	49	11	research	research	NOUN
dpc-4195	49	12	letter	letter	NOUN
dpc-4195	49	13	|	|	ADV
dpc-4195	49	14	dermatol	dermatol	ADJ
dpc-4195	49	15	pract	pract	NOUN
dpc-4195	49	16	concept	concept	NOUN
dpc-4195	49	17	.	.	PUNCT
dpc-4195	50	1	2024;14(3):e2024186	2024;14(3):e2024186	NUM
dpc-4195	50	2	3	3	NUM
dpc-4195	50	3	easi-90	easi-90	NOUN
dpc-4195	50	4	effect	effect	NOUN
dpc-4195	50	5	in	in	ADP
dpc-4195	50	6	2/6	2/6	NUM
dpc-4195	50	7	patients	patient	NOUN
dpc-4195	50	8	after	after	ADP
dpc-4195	50	9	4	4	NUM
dpc-4195	50	10	months	month	NOUN
dpc-4195	50	11	(	(	PUNCT
dpc-4195	50	12	patients	patient	NOUN
dpc-4195	50	13	#	#	SYM
dpc-4195	50	14	3	3	NUM
dpc-4195	50	15	and	and	CCONJ
dpc-4195	50	16	#	#	SYM
dpc-4195	50	17	6	6	NUM
dpc-4195	50	18	)	)	PUNCT
dpc-4195	50	19	.	.	PUNCT
dpc-4195	51	1	these	these	DET
dpc-4195	51	2	2	2	NUM
dpc-4195	51	3	patients	patient	NOUN
dpc-4195	51	4	were	be	AUX
dpc-4195	51	5	found	find	VERB
dpc-4195	51	6	to	to	PART
dpc-4195	51	7	have	have	VERB
dpc-4195	51	8	lower	low	ADJ
dpc-4195	51	9	baseline	baseline	VERB
dpc-4195	51	10	easi	easi	NOUN
dpc-4195	51	11	scores	score	NOUN
dpc-4195	51	12	under	under	ADP
dpc-4195	51	13	previous	previous	ADJ
dpc-4195	51	14	treatment	treatment	NOUN
dpc-4195	51	15	with	with	ADP
dpc-4195	51	16	phototherapy	phototherapy	NOUN
dpc-4195	51	17	.	.	PUNCT
dpc-4195	52	1	this	this	DET
dpc-4195	52	2	observation	observation	NOUN
dpc-4195	52	3	suggests	suggest	VERB
dpc-4195	52	4	that	that	SCONJ
dpc-4195	52	5	in	in	ADP
dpc-4195	52	6	ad	ad	NOUN
dpc-4195	52	7	patients	patient	NOUN
dpc-4195	52	8	with	with	ADP
dpc-4195	52	9	less	less	ADV
dpc-4195	52	10	severe	severe	ADJ
dpc-4195	52	11	skin	skin	NOUN
dpc-4195	52	12	lesions	lesion	NOUN
dpc-4195	52	13	,	,	PUNCT
dpc-4195	52	14	easi-90	easi-90	NUM
dpc-4195	52	15	response	response	NOUN
dpc-4195	52	16	may	may	AUX
dpc-4195	52	17	be	be	AUX
dpc-4195	52	18	maintained	maintain	VERB
dpc-4195	52	19	after	after	SCONJ
dpc-4195	52	20	upadacitinib	upadacitinib	NOUN
dpc-4195	52	21	dosage	dosage	NOUN
dpc-4195	52	22	is	be	AUX
dpc-4195	52	23	tapered	taper	VERB
dpc-4195	52	24	.	.	PUNCT
dpc-4195	53	1	of	of	ADP
dpc-4195	53	2	note	note	NOUN
dpc-4195	53	3	,	,	PUNCT
dpc-4195	53	4	patient	patient	ADJ
dpc-4195	53	5	5	5	NUM
dpc-4195	53	6	failed	fail	VERB
dpc-4195	53	7	to	to	PART
dpc-4195	53	8	achieve	achieve	VERB
dpc-4195	53	9	easi-90	easi-90	NOUN
dpc-4195	53	10	after	after	ADP
dpc-4195	53	11	high	high	ADJ
dpc-4195	53	12	-	-	PUNCT
dpc-4195	53	13	dose	dose	VERB
dpc-4195	53	14	upadacitinib	upadacitinib	NOUN
dpc-4195	53	15	treatment	treatment	NOUN
dpc-4195	53	16	for	for	ADP
dpc-4195	53	17	3	3	NUM
dpc-4195	53	18	months	month	NOUN
dpc-4195	53	19	.	.	PUNCT
dpc-4195	54	1	serum	serum	PROPN
dpc-4195	54	2	total	total	ADJ
dpc-4195	54	3	immunoglobulin	immunoglobulin	PROPN
dpc-4195	54	4	e	e	PROPN
dpc-4195	54	5	(	(	PUNCT
dpc-4195	54	6	ige	ige	PROPN
dpc-4195	54	7	)	)	PUNCT
dpc-4195	54	8	has	have	AUX
dpc-4195	54	9	been	be	AUX
dpc-4195	54	10	indicated	indicate	VERB
dpc-4195	54	11	as	as	ADP
dpc-4195	54	12	a	a	DET
dpc-4195	54	13	potential	potential	ADJ
dpc-4195	54	14	biomarker	biomarker	NOUN
dpc-4195	54	15	for	for	ADP
dpc-4195	54	16	treatment	treatment	NOUN
dpc-4195	54	17	response	response	NOUN
dpc-4195	54	18	of	of	ADP
dpc-4195	54	19	ad	ad	NOUN
dpc-4195	54	20	5,6	5,6	NUM
dpc-4195	54	21	.	.	PUNCT
dpc-4195	55	1	patient	patient	NOUN
dpc-4195	55	2	5	5	NUM
dpc-4195	55	3	was	be	AUX
dpc-4195	55	4	found	find	VERB
dpc-4195	55	5	to	to	PART
dpc-4195	55	6	show	show	VERB
dpc-4195	55	7	elevation	elevation	NOUN
dpc-4195	55	8	of	of	ADP
dpc-4195	55	9	serum	serum	PROPN
dpc-4195	55	10	ige	ige	PROPN
dpc-4195	55	11	from	from	ADP
dpc-4195	55	12	17508	17508	NUM
dpc-4195	55	13	to	to	ADP
dpc-4195	55	14	24860	24860	NUM
dpc-4195	55	15	iu	iu	ADP
dpc-4195	55	16	/	/	SYM
dpc-4195	55	17	ml	ml	VERB
dpc-4195	55	18	during	during	ADP
dpc-4195	55	19	upadacitinib	upadacitinib	NOUN
dpc-4195	55	20	treatment	treatment	NOUN
dpc-4195	55	21	.	.	PUNCT
dpc-4195	56	1	this	this	DET
dpc-4195	56	2	observation	observation	NOUN
dpc-4195	56	3	suggests	suggest	VERB
dpc-4195	56	4	that	that	SCONJ
dpc-4195	56	5	extremely	extremely	ADV
dpc-4195	56	6	high	high	ADJ
dpc-4195	56	7	ige	ige	NOUN
dpc-4195	56	8	level	level	NOUN
dpc-4195	56	9	and	and	CCONJ
dpc-4195	56	10	failure	failure	NOUN
dpc-4195	56	11	to	to	PART
dpc-4195	56	12	show	show	VERB
dpc-4195	56	13	reducing	reduce	VERB
dpc-4195	56	14	ige	ige	NOUN
dpc-4195	56	15	level	level	NOUN
dpc-4195	56	16	during	during	ADP
dpc-4195	56	17	treatment	treatment	NOUN
dpc-4195	56	18	may	may	AUX
dpc-4195	56	19	indicate	indicate	VERB
dpc-4195	56	20	a	a	DET
dpc-4195	56	21	poor	poor	ADJ
dpc-4195	56	22	response	response	NOUN
dpc-4195	56	23	.	.	PUNCT
dpc-4195	57	1	conclusions	conclusion	NOUN
dpc-4195	57	2	upadacitinib	upadacitinib	VERB
dpc-4195	57	3	15	15	NUM
dpc-4195	57	4	mg	mg	NOUN
dpc-4195	57	5	daily	daily	ADV
dpc-4195	57	6	can	can	AUX
dpc-4195	57	7	be	be	AUX
dpc-4195	57	8	used	use	VERB
dpc-4195	57	9	as	as	ADP
dpc-4195	57	10	a	a	DET
dpc-4195	57	11	maintenance	maintenance	NOUN
dpc-4195	57	12	therapy	therapy	NOUN
dpc-4195	57	13	in	in	ADP
dpc-4195	57	14	patients	patient	NOUN
dpc-4195	57	15	with	with	ADP
dpc-4195	57	16	moderate	moderate	ADJ
dpc-4195	57	17	ad	ad	NOUN
dpc-4195	57	18	after	after	ADP
dpc-4195	57	19	achieving	achieve	VERB
dpc-4195	57	20	easi-90	easi-90	NOUN
dpc-4195	57	21	to	to	PART
dpc-4195	57	22	balance	balance	VERB
dpc-4195	57	23	the	the	DET
dpc-4195	57	24	efficacy	efficacy	NOUN
dpc-4195	57	25	and	and	CCONJ
dpc-4195	57	26	cost	cost	NOUN
dpc-4195	57	27	in	in	ADP
dpc-4195	57	28	real	real	ADJ
dpc-4195	57	29	-	-	PUNCT
dpc-4195	57	30	world	world	NOUN
dpc-4195	57	31	practice	practice	NOUN
dpc-4195	57	32	.	.	PUNCT
dpc-4195	58	1	references	reference	NOUN
dpc-4195	58	2	1	1	X
dpc-4195	58	3	.	.	PUNCT
dpc-4195	59	1	pariser	pariser	PROPN
dpc-4195	59	2	dm	dm	PROPN
dpc-4195	59	3	,	,	PUNCT
dpc-4195	59	4	simpson	simpson	PROPN
dpc-4195	59	5	el	el	PROPN
dpc-4195	59	6	,	,	PUNCT
dpc-4195	59	7	gadkari	gadkari	PROPN
dpc-4195	59	8	a	a	X
dpc-4195	59	9	,	,	PUNCT
dpc-4195	59	10	et	et	PROPN
dpc-4195	59	11	al	al	PROPN
dpc-4195	59	12	.	.	PUNCT
dpc-4195	59	13	evaluating	evaluate	VERB
dpc-4195	59	14	patient	patient	NOUN
dpc-4195	59	15	-	-	PUNCT
dpc-4195	59	16	perceived	perceive	VERB
dpc-4195	59	17	control	control	NOUN
dpc-4195	59	18	of	of	ADP
dpc-4195	59	19	atopic	atopic	NOUN
dpc-4195	59	20	dermatitis	dermatitis	NOUN
dpc-4195	59	21	:	:	PUNCT
dpc-4195	59	22	design	design	NOUN
dpc-4195	59	23	,	,	PUNCT
dpc-4195	59	24	validation	validation	NOUN
dpc-4195	59	25	,	,	PUNCT
dpc-4195	59	26	and	and	CCONJ
dpc-4195	59	27	scoring	scoring	NOUN
dpc-4195	59	28	of	of	ADP
dpc-4195	59	29	the	the	DET
dpc-4195	59	30	atopic	atopic	NOUN
dpc-4195	59	31	dermatitis	dermatitis	NOUN
dpc-4195	59	32	control	control	NOUN
dpc-4195	59	33	tool	tool	NOUN
dpc-4195	59	34	(	(	PUNCT
dpc-4195	59	35	adct	adct	PROPN
dpc-4195	59	36	)	)	PUNCT
dpc-4195	59	37	.	.	PUNCT
dpc-4195	60	1	curr	curr	PROPN
dpc-4195	60	2	med	med	PROPN
dpc-4195	60	3	res	re	NOUN
dpc-4195	60	4	opin	opin	NOUN
dpc-4195	60	5	.	.	PUNCT
dpc-4195	61	1	2020;36(3):367	2020;36(3):367	NUM
dpc-4195	61	2	-	-	SYM
dpc-4195	61	3	376	376	NUM
dpc-4195	61	4	.	.	PUNCT
dpc-4195	62	1	doi	doi	NOUN
dpc-4195	62	2	:	:	PUNCT
dpc-4195	62	3	10.1080	10.1080	NUM
dpc-4195	62	4	/03007995.2019.1699516	/03007995.2019.1699516	NUM
dpc-4195	62	5	.	.	PUNCT
dpc-4195	63	1	pmid	pmid	NOUN
dpc-4195	63	2	:	:	PUNCT
dpc-4195	63	3	31778083	31778083	NUM
dpc-4195	63	4	.	.	PUNCT
dpc-4195	64	1	2	2	X
dpc-4195	64	2	.	.	X
dpc-4195	64	3	reich	reich	PROPN
dpc-4195	64	4	k	k	PROPN
dpc-4195	64	5	,	,	PUNCT
dpc-4195	64	6	teixeira	teixeira	PROPN
dpc-4195	64	7	hd	hd	PROPN
dpc-4195	64	8	,	,	PUNCT
dpc-4195	64	9	de	de	X
dpc-4195	64	10	bruin	bruin	NOUN
dpc-4195	64	11	-	-	PUNCT
dpc-4195	64	12	weller	weller	PROPN
dpc-4195	64	13	m	m	PROPN
dpc-4195	64	14	,	,	PUNCT
dpc-4195	64	15	et	et	PROPN
dpc-4195	64	16	al	al	PROPN
dpc-4195	64	17	.	.	PROPN
dpc-4195	64	18	safety	safety	NOUN
dpc-4195	64	19	and	and	CCONJ
dpc-4195	64	20	efficacy	efficacy	NOUN
dpc-4195	64	21	of	of	ADP
dpc-4195	64	22	upadacitinib	upadacitinib	NOUN
dpc-4195	64	23	in	in	ADP
dpc-4195	64	24	combination	combination	NOUN
dpc-4195	64	25	with	with	ADP
dpc-4195	64	26	topical	topical	ADJ
dpc-4195	64	27	corticosteroids	corticosteroid	NOUN
dpc-4195	64	28	in	in	ADP
dpc-4195	64	29	adolescents	adolescent	NOUN
dpc-4195	64	30	and	and	CCONJ
dpc-4195	64	31	adults	adult	NOUN
dpc-4195	64	32	with	with	ADP
dpc-4195	64	33	moderate	moderate	ADJ
dpc-4195	64	34	-	-	PUNCT
dpc-4195	64	35	to	to	ADP
dpc-4195	64	36	-	-	PUNCT
dpc-4195	64	37	severe	severe	ADJ
dpc-4195	64	38	atopic	atopic	NOUN
dpc-4195	64	39	dermatitis	dermatitis	NOUN
dpc-4195	64	40	(	(	PUNCT
dpc-4195	64	41	ad	ad	NOUN
dpc-4195	64	42	up	up	ADP
dpc-4195	64	43	):	):	PUNCT
dpc-4195	64	44	results	result	NOUN
dpc-4195	64	45	from	from	ADP
dpc-4195	64	46	a	a	DET
dpc-4195	64	47	randomised	randomised	ADJ
dpc-4195	64	48	,	,	PUNCT
dpc-4195	64	49	double	double	ADJ
dpc-4195	64	50	-	-	PUNCT
dpc-4195	64	51	blind	blind	ADJ
dpc-4195	64	52	,	,	PUNCT
dpc-4195	64	53	placebo	placebo	NOUN
dpc-4195	64	54	controlled	control	VERB
dpc-4195	64	55	,	,	PUNCT
dpc-4195	64	56	phase	phase	NOUN
dpc-4195	64	57	3	3	NUM
dpc-4195	64	58	trial	trial	NOUN
dpc-4195	64	59	.	.	PUNCT
dpc-4195	65	1	lancet	lancet	PROPN
dpc-4195	65	2	.	.	PUNCT
dpc-4195	66	1	jun	jun	PROPN
dpc-4195	66	2	5	5	NUM
dpc-4195	66	3	2021;397(10290	2021;397(10290	NUM
dpc-4195	66	4	):	):	PUNCT
dpc-4195	66	5	2169	2169	NUM
dpc-4195	66	6	-	-	SYM
dpc-4195	66	7	2181	2181	NUM
dpc-4195	66	8	.	.	PUNCT
dpc-4195	67	1	doi:10.1016	doi:10.1016	PROPN
dpc-4195	67	2	/	/	SYM
dpc-4195	67	3	s0140	s0140	PROPN
dpc-4195	67	4	-	-	PUNCT
dpc-4195	67	5	6736(21)00589	6736(21)00589	NUM
dpc-4195	67	6	-	-	SYM
dpc-4195	67	7	4	4	NUM
dpc-4195	67	8	3	3	NUM
dpc-4195	67	9	.	.	PUNCT
dpc-4195	68	1	guttman	guttman	ADJ
dpc-4195	68	2	-	-	PUNCT
dpc-4195	68	3	yassky	yassky	NOUN
dpc-4195	68	4	e	e	NOUN
dpc-4195	68	5	,	,	PUNCT
dpc-4195	68	6	teixeira	teixeira	PROPN
dpc-4195	68	7	hd	hd	PROPN
dpc-4195	68	8	,	,	PUNCT
dpc-4195	68	9	simpson	simpson	PROPN
dpc-4195	68	10	el	el	PROPN
dpc-4195	68	11	,	,	PUNCT
dpc-4195	68	12	et	et	PROPN
dpc-4195	68	13	al	al	PROPN
dpc-4195	68	14	.	.	PROPN
dpc-4195	69	1	once	once	ADV
dpc-4195	69	2	-	-	PUNCT
dpc-4195	69	3	daily	daily	ADJ
dpc-4195	69	4	upadacitinib	upadacitinib	NOUN
dpc-4195	69	5	versus	versus	ADP
dpc-4195	69	6	placebo	placebo	NOUN
dpc-4195	69	7	in	in	ADP
dpc-4195	69	8	adolescents	adolescent	NOUN
dpc-4195	69	9	and	and	CCONJ
dpc-4195	69	10	adults	adult	NOUN
dpc-4195	69	11	with	with	ADP
dpc-4195	69	12	moderate	moderate	ADJ
dpc-4195	69	13	-	-	PUNCT
dpc-4195	69	14	to	to	ADP
dpc-4195	69	15	-	-	PUNCT
dpc-4195	69	16	severe	severe	ADJ
dpc-4195	69	17	atopic	atopic	NOUN
dpc-4195	69	18	dermatitis	dermatitis	NOUN
dpc-4195	69	19	(	(	PUNCT
dpc-4195	69	20	measure	measure	VERB
dpc-4195	69	21	up	up	ADV
dpc-4195	69	22	1	1	NUM
dpc-4195	69	23	and	and	CCONJ
dpc-4195	69	24	measure	measure	VERB
dpc-4195	69	25	up	up	ADV
dpc-4195	69	26	2	2	NUM
dpc-4195	69	27	):	):	PUNCT
dpc-4195	69	28	results	result	NOUN
dpc-4195	69	29	from	from	ADP
dpc-4195	69	30	two	two	NUM
dpc-4195	69	31	replicate	replicate	ADJ
dpc-4195	69	32	double	double	ADJ
dpc-4195	69	33	-	-	PUNCT
dpc-4195	69	34	blind	blind	ADJ
dpc-4195	69	35	,	,	PUNCT
dpc-4195	69	36	randomised	randomise	VERB
dpc-4195	69	37	controlled	control	VERB
dpc-4195	69	38	phase	phase	NOUN
dpc-4195	69	39	3	3	NUM
dpc-4195	69	40	trials	trial	NOUN
dpc-4195	69	41	.	.	PUNCT
dpc-4195	70	1	lancet	lancet	PROPN
dpc-4195	70	2	.	.	PUNCT
dpc-4195	71	1	jun	jun	PROPN
dpc-4195	71	2	5	5	NUM
dpc-4195	71	3	2021;397(10290	2021;397(10290	NUM
dpc-4195	71	4	):	):	PUNCT
dpc-4195	71	5	2151	2151	NUM
dpc-4195	71	6	-	-	SYM
dpc-4195	71	7	2168	2168	NUM
dpc-4195	71	8	.	.	PUNCT
dpc-4195	72	1	doi:10.1016	doi:10.1016	PROPN
dpc-4195	72	2	/	/	SYM
dpc-4195	72	3	s0140	s0140	PROPN
dpc-4195	72	4	-	-	PUNCT
dpc-4195	72	5	6736(21)00588	6736(21)00588	NOUN
dpc-4195	72	6	-	-	SYM
dpc-4195	72	7	2	2	NUM
dpc-4195	72	8	4	4	NUM
dpc-4195	72	9	.	.	PUNCT
dpc-4195	72	10	blauvelt	blauvelt	VERB
dpc-4195	72	11	a	a	DET
dpc-4195	72	12	,	,	PUNCT
dpc-4195	72	13	teixeira	teixeira	PROPN
dpc-4195	72	14	hd	hd	PROPN
dpc-4195	72	15	,	,	PUNCT
dpc-4195	72	16	simpson	simpson	PROPN
dpc-4195	72	17	el	el	PROPN
dpc-4195	72	18	,	,	PUNCT
dpc-4195	72	19	et	et	PROPN
dpc-4195	72	20	al	al	PROPN
dpc-4195	72	21	.	.	PROPN
dpc-4195	72	22	efficacy	efficacy	NOUN
dpc-4195	72	23	and	and	CCONJ
dpc-4195	72	24	safety	safety	NOUN
dpc-4195	72	25	of	of	ADP
dpc-4195	72	26	upadacitinib	upadacitinib	NOUN
dpc-4195	72	27	vs	vs	ADP
dpc-4195	72	28	dupilumab	dupilumab	NOUN
dpc-4195	72	29	in	in	ADP
dpc-4195	72	30	adults	adult	NOUN
dpc-4195	72	31	with	with	ADP
dpc-4195	72	32	moderate	moderate	ADJ
dpc-4195	72	33	-	-	PUNCT
dpc-4195	72	34	to	to	ADP
dpc-4195	72	35	-	-	PUNCT
dpc-4195	72	36	severe	severe	ADJ
dpc-4195	72	37	atopic	atopic	NOUN
dpc-4195	72	38	dermatitis	dermatitis	NOUN
dpc-4195	72	39	:	:	PUNCT
dpc-4195	72	40	a	a	DET
dpc-4195	72	41	randomized	randomized	ADJ
dpc-4195	72	42	clinical	clinical	ADJ
dpc-4195	72	43	trial	trial	NOUN
dpc-4195	72	44	.	.	PUNCT
dpc-4195	73	1	jama	jama	PROPN
dpc-4195	73	2	dermatol	dermatol	NOUN
dpc-4195	73	3	.	.	PUNCT
dpc-4195	74	1	sep	sep	PROPN
dpc-4195	74	2	1	1	NUM
dpc-4195	74	3	2021;157(9):1047	2021;157(9):1047	NUM
dpc-4195	74	4	-	-	NUM
dpc-4195	74	5	1055	1055	NUM
dpc-4195	74	6	.	.	PUNCT
dpc-4195	75	1	doi:10.1001	doi:10.1001	PROPN
dpc-4195	75	2	/	/	SYM
dpc-4195	75	3	jamadermatol	jamadermatol	NOUN
dpc-4195	75	4	.2021.3023	.2021.3023	PROPN
dpc-4195	76	1	5	5	X
dpc-4195	76	2	.	.	PUNCT
dpc-4195	76	3	kiiski	kiiski	PROPN
dpc-4195	76	4	v	v	PROPN
dpc-4195	76	5	,	,	PUNCT
dpc-4195	76	6	karlsson	karlsson	PROPN
dpc-4195	76	7	o	o	PROPN
dpc-4195	76	8	,	,	PUNCT
dpc-4195	76	9	remitz	remitz	NOUN
dpc-4195	76	10	a	a	PRON
dpc-4195	76	11	,	,	PUNCT
dpc-4195	76	12	reitamo	reitamo	NOUN
dpc-4195	76	13	s.	s.	PROPN
dpc-4195	76	14	high	high	PROPN
dpc-4195	76	15	serum	serum	PROPN
dpc-4195	76	16	total	total	PROPN
dpc-4195	76	17	ige	ige	PROPN
dpc-4195	76	18	predicts	predict	VERB
dpc-4195	76	19	poor	poor	ADJ
dpc-4195	76	20	long	long	ADJ
dpc-4195	76	21	-	-	PUNCT
dpc-4195	76	22	term	term	NOUN
dpc-4195	76	23	outcome	outcome	NOUN
dpc-4195	76	24	in	in	ADP
dpc-4195	76	25	atopic	atopic	NOUN
dpc-4195	76	26	dermatitis	dermatitis	NOUN
dpc-4195	76	27	.	.	PUNCT
dpc-4195	77	1	acta	acta	PROPN
dpc-4195	77	2	derm	derm	PROPN
dpc-4195	77	3	venereol	venereol	NOUN
dpc-4195	77	4	.	.	PUNCT
dpc-4195	78	1	nov	nov	PROPN
dpc-4195	78	2	2015;95(8):943	2015;95(8):943	NUM
dpc-4195	78	3	-	-	SYM
dpc-4195	78	4	7	7	NUM
dpc-4195	78	5	.	.	PUNCT
dpc-4195	78	6	doi:10.2340/00015555	doi:10.2340/00015555	NOUN
dpc-4195	78	7	-2126	-2126	NOUN
dpc-4195	79	1	6	6	NUM
dpc-4195	79	2	.	.	PUNCT
dpc-4195	80	1	huang	huang	PROPN
dpc-4195	80	2	th	th	PROPN
dpc-4195	80	3	,	,	PUNCT
dpc-4195	80	4	chen	chen	PROPN
dpc-4195	80	5	yc	yc	PROPN
dpc-4195	80	6	,	,	PUNCT
dpc-4195	80	7	lin	lin	PROPN
dpc-4195	80	8	sy	sy	PROPN
dpc-4195	80	9	,	,	PUNCT
dpc-4195	80	10	et	et	PROPN
dpc-4195	80	11	al	al	PROPN
dpc-4195	80	12	.	.	PUNCT
dpc-4195	81	1	treatment	treatment	NOUN
dpc-4195	81	2	of	of	ADP
dpc-4195	81	3	atopic	atopic	NOUN
dpc-4195	81	4	dermatitis	dermatitis	NOUN
dpc-4195	81	5	with	with	ADP
dpc-4195	81	6	dupilumab	dupilumab	NOUN
dpc-4195	81	7	in	in	ADP
dpc-4195	81	8	taiwan	taiwan	PROPN
dpc-4195	81	9	:	:	PUNCT
dpc-4195	81	10	dynamic	dynamic	ADJ
dpc-4195	81	11	changes	change	NOUN
dpc-4195	81	12	of	of	ADP
dpc-4195	81	13	ige	ige	PROPN
dpc-4195	81	14	levels	level	NOUN
dpc-4195	81	15	as	as	ADP
dpc-4195	81	16	a	a	DET
dpc-4195	81	17	potential	potential	ADJ
dpc-4195	81	18	response	response	NOUN
dpc-4195	81	19	biomarker	biomarker	NOUN
dpc-4195	81	20	.	.	PUNCT
dpc-4195	82	1	eur	eur	PROPN
dpc-4195	82	2	j	j	PROPN
dpc-4195	82	3	dermatol	dermatol	NOUN
dpc-4195	82	4	.	.	PUNCT
dpc-4195	83	1	dec	dec	PROPN
dpc-4195	83	2	1	1	NUM
dpc-4195	83	3	2019;29(6):658	2019;29(6):658	NUM
dpc-4195	83	4	-	-	PUNCT
dpc-4195	83	5	659	659	NUM
dpc-4195	83	6	.	.	PUNCT
dpc-4195	83	7	doi:10.1684	doi:10.1684	NOUN
dpc-4195	83	8	/	/	SYM
dpc-4195	83	9	ejd.2019.3661	ejd.2019.3661	VERB
dpc-4195	83	10	figure	figure	NOUN
dpc-4195	83	11	2	2	NUM
dpc-4195	83	12	.	.	PUNCT
dpc-4195	83	13	improvement	improvement	NOUN
dpc-4195	83	14	of	of	ADP
dpc-4195	83	15	disease	disease	NOUN
dpc-4195	83	16	severity	severity	NOUN
dpc-4195	83	17	assessed	assess	VERB
dpc-4195	83	18	through	through	ADP
dpc-4195	83	19	percentage	percentage	NOUN
dpc-4195	83	20	change	change	NOUN
dpc-4195	83	21	in	in	ADP
dpc-4195	83	22	eczema	eczema	PROPN
dpc-4195	83	23	area	area	NOUN
dpc-4195	83	24	and	and	CCONJ
dpc-4195	83	25	severity	severity	NOUN
dpc-4195	83	26	index	index	NOUN
dpc-4195	83	27	(	(	PUNCT
dpc-4195	83	28	δeasi	δeasi	PROPN
dpc-4195	83	29	)	)	PUNCT
dpc-4195	83	30	(	(	PUNCT
dpc-4195	83	31	a	a	X
dpc-4195	83	32	)	)	PUNCT
dpc-4195	83	33	and	and	CCONJ
dpc-4195	83	34	atopic	atopic	NOUN
dpc-4195	83	35	dermatitis	dermatitis	NOUN
dpc-4195	83	36	control	control	NOUN
dpc-4195	83	37	tool	tool	NOUN
dpc-4195	83	38	(	(	PUNCT
dpc-4195	83	39	adct	adct	PROPN
dpc-4195	83	40	)	)	PUNCT
dpc-4195	83	41	scores	score	NOUN
dpc-4195	83	42	(	(	PUNCT
dpc-4195	83	43	b	b	NOUN
dpc-4195	83	44	)	)	PUNCT
dpc-4195	83	45	after	after	ADP
dpc-4195	83	46	treatment	treatment	NOUN
dpc-4195	83	47	with	with	ADP
dpc-4195	83	48	upadacitinib	upadacitinib	NOUN
dpc-4195	83	49	.	.	PUNCT
dpc-4195	84	1	disease	disease	NOUN
dpc-4195	84	2	severity	severity	NOUN
dpc-4195	84	3	was	be	AUX
dpc-4195	84	4	followed	follow	VERB
dpc-4195	84	5	up	up	ADP
dpc-4195	84	6	within	within	ADP
dpc-4195	84	7	one	one	NUM
dpc-4195	84	8	month	month	NOUN
dpc-4195	84	9	after	after	ADP
dpc-4195	84	10	discontinuation	discontinuation	NOUN
dpc-4195	84	11	of	of	ADP
dpc-4195	84	12	upadacitinib	upadacitinib	NOUN
dpc-4195	84	13	.	.	PUNCT
dpc-4195	85	1	the	the	DET
dpc-4195	85	2	improvement	improvement	NOUN
dpc-4195	85	3	in	in	ADP
dpc-4195	85	4	easi	easi	NOUN
dpc-4195	85	5	scores	score	NOUN
dpc-4195	85	6	generally	generally	ADV
dpc-4195	85	7	correlates	correlate	VERB
dpc-4195	85	8	with	with	ADP
dpc-4195	85	9	improvement	improvement	NOUN
dpc-4195	85	10	in	in	ADP
dpc-4195	85	11	adct	adct	ADJ
dpc-4195	85	12	scores	score	NOUN
dpc-4195	85	13	.	.	PUNCT
dpc-4195	86	1	notably	notably	ADV
dpc-4195	86	2	,	,	PUNCT
dpc-4195	86	3	patients	patient	NOUN
dpc-4195	86	4	#	#	SYM
dpc-4195	86	5	5	5	NUM
dpc-4195	86	6	and	and	CCONJ
dpc-4195	86	7	#	#	SYM
dpc-4195	86	8	7	7	NUM
dpc-4195	86	9	had	have	VERB
dpc-4195	86	10	relatively	relatively	ADV
dpc-4195	86	11	fluctuated	fluctuate	VERB
dpc-4195	86	12	disease	disease	NOUN
dpc-4195	86	13	severity	severity	NOUN
dpc-4195	86	14	(	(	PUNCT
dpc-4195	86	15	adct	adct	PROPN
dpc-4195	86	16	score	score	NOUN
dpc-4195	86	17	)	)	PUNCT
dpc-4195	86	18	during	during	ADP
dpc-4195	86	19	upadacitinib	upadacitinib	NOUN
dpc-4195	86	20	treatment	treatment	NOUN
dpc-4195	86	21	.	.	PUNCT
dpc-4195	87	1	patients	patient	NOUN
dpc-4195	87	2	#	#	SYM
dpc-4195	87	3	4	4	NUM
dpc-4195	87	4	and	and	CCONJ
dpc-4195	87	5	#	#	SYM
dpc-4195	87	6	6	6	NUM
dpc-4195	87	7	had	have	VERB
dpc-4195	87	8	stable	stable	ADJ
dpc-4195	87	9	easi	easi	NOUN
dpc-4195	87	10	and	and	CCONJ
dpc-4195	87	11	adct	adct	ADJ
dpc-4195	87	12	scores	score	NOUN
dpc-4195	87	13	after	after	ADP
dpc-4195	87	14	discontinuation	discontinuation	NOUN
dpc-4195	87	15	of	of	ADP
dpc-4195	87	16	upadacitinib	upadacitinib	NOUN
dpc-4195	87	17	.	.	PUNCT
dpc-4195	88	1	adct	adct	ADJ
dpc-4195	88	2	score	score	NOUN
dpc-4195	88	3	above	above	ADP
dpc-4195	88	4	7	7	NUM
dpc-4195	88	5	points	point	NOUN
dpc-4195	88	6	is	be	AUX
dpc-4195	88	7	thought	think	VERB
dpc-4195	88	8	to	to	PART
dpc-4195	88	9	indicate	indicate	VERB
dpc-4195	88	10	inadequate	inadequate	ADJ
dpc-4195	88	11	control	control	NOUN
dpc-4195	88	12	over	over	ADP
dpc-4195	88	13	atopic	atopic	NOUN
dpc-4195	88	14	dermatitis	dermatitis	NOUN
dpc-4195	88	15	,	,	PUNCT
dpc-4195	88	16	whereas	whereas	SCONJ
dpc-4195	88	17	an	an	DET
dpc-4195	88	18	increase	increase	NOUN
dpc-4195	88	19	of	of	ADP
dpc-4195	88	20	5	5	NUM
dpc-4195	88	21	points	point	NOUN
dpc-4195	88	22	indicates	indicate	VERB
dpc-4195	88	23	a	a	DET
dpc-4195	88	24	worsening	worsening	NOUN
dpc-4195	88	25	of	of	ADP
dpc-4195	88	26	disease	disease	NOUN
dpc-4195	88	27	control	control	NOUN
dpc-4195	88	28	.	.	PUNCT